Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice

This is a phase 4, multicenter, randomized, non-therapeutic interventional trial in subjects with psoriasis looking for the prevalence of psoriatic arthritis. Subjects will be seen and evaluated by a dermatologist at visit 1 and by a rheumatologist at visit 2. A subset of subjects will then go on to visit 3 for imaging procedures (x-ray, MRI, and ultrasound).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psoriasis Arthritis Arthritis, Psoriatic Bone Diseases Joint Diseases Musculoskeletal Diseases Psoriatic Arthritis Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Spinal Diseases Spondylarthritis Spondylarthropathies Spondylitis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Universitair Ziekenhuis Gent, Ghent, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subject is >18 years of age at the time of consent.
Subject has a confirmed diagnosis of plaque psoriasis by clinical judgment.
Subject is able to read and complete questionnaires.
Subjects planning to undergo radiographic evaluation, should not have any contraindications to MRI.

Exclusion criteria

None.

Treatment and study plan

lab draws and imaging

Procedure

1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI

Primary outcomes

Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results

Time frame: Week 0 through Week 8

PsA: inflammatory arthritis associated with psoriasis that can have an indolent and progressive course. Percentage of participants with PsA was calculated by dividing the number of participants who were classified as positive by the rheumatologist and the total number of participants evaluated using medical history, physical examination and laboratory results as the basis for the diagnosis.

Secondary outcomes

Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination and Medical History

Time frame: Week 0 through Week 8

PsA: inflammatory arthritis associated with psoriasis that can have an indolent and progressive course. Percentage of participants with PsA was calculated by dividing the number of participants who were classified as positive by the rheumatologist and the total number of participants evaluated using medical history and physical examination as the basis for the diagnosis.
Percentage of Participants With Undiagnosed Psoriatic Arthritis (PsA)

Time frame: Week 0 through Week 8

PsA: inflammatory arthritis associated with psoriasis that can have an indolent and progressive course. Primary PsA diagnosis made by rheumatologist based on physical examination, medical history and laboratory test results. Secondary PsA diagnosis made by rheumatologist based on physical examination and medical history only. For both, numerator was number of participants with "No" answer to question concerning previous diagnosis of PsA at Visit 1 (dermatology visit) and were subsequently classified as positive by rheumatologist; denominator was total number of participants evaluated for PsA.

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Acronym: PREPARE

Important dates

Study start: 2010
Primary completion: 2011
Study completion: 2011
First posted: Jun 22, 2010
Registry last updated: Jun 21, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed